Related Experiment Videos
New antifungal agents
1University of Texas Health Science Center, San Antonio 78284.
Abstract:
For more than two decades, amphotericin B has been the single broad-spectrum agent for the treatment of systemic mycoses. Amphotericin B is not always effective, must be given parenterally, and is associated with a host of adverse reactions. Despite amphotericin B toxicity, until recently the systemic mycoses did not rate enough attention to prompt a search for new alternatives. However, three recent events have overcome this inertia: the gradually increasing use of potent immunosuppressive agents and broad-spectrum antibacterial drugs; the discovery of the relatively nontoxic azole classes of antifungal drugs in the 1980s and the rapid emergence of AIDS, with its severe accompanying opportunistic fungal infections. In just ten years we have seen the emergence of second-generation imidazole and third-generation triazole antifungal drugs and, most recently, entirely new classes of agents. It is remarkable that so many alternatives are becoming available just at the time when new antifungal drugs have become a major need. This discussion will concentrate on the new antifungal drugs of the past ten years, with the exception of developments in the polyenes and flucytosine, which are covered elsewhere.
Insights
New antifungal drugs offer alternatives to older treatments like amphotericin B, addressing rising needs due to immunosuppression and AIDS. This review focuses on novel antifungal agents from the last decade.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Amphotericin B has been the primary systemic antifungal for over 20 years but has limitations including parenteral administration and toxicity.
- The emergence of AIDS and increased use of immunosuppressive agents have highlighted the need for new antifungal treatments.
- Recent advances include the development of azole antifungals and entirely new classes of agents.
Purpose of the Study:
- To review novel antifungal drugs developed in the past ten years.
- To discuss the impact of new antifungal agents on treating systemic mycoses.
- To highlight the growing need for effective antifungal therapies.
Main Methods:
- Literature review focusing on antifungal drug development over the last decade.
- Analysis of new antifungal classes, including imidazoles and triazoles.
- Exclusion of developments in polyenes and flucytosine.
Main Results:
- Significant advancements in antifungal drug discovery have occurred in the last ten years.
- Second-generation imidazole and third-generation triazole antifungals have emerged.
- Entirely new classes of antifungal agents are now available.
Conclusions:
- The development of new antifungal drugs is timely, addressing critical unmet needs in treating systemic fungal infections.
- The expanding arsenal of antifungal therapies offers improved options for patients, particularly those who are immunocompromised.
- Continued research and development in antifungal pharmacotherapy are essential.